HLA-B and neoplasm: Future studies aimed to evaluate the in vivo anti-tumor activity of EpCAM-ReTARGTPRIFNαR149A should use tumor-bearing mice engrafted with peripheral blood mononuclear cells (PBMCs) from CMV-seropositive/HLA-B*07:02-matched donors.